Evaluation of Anxiety and Depression in Idiopathic Pulmonary Fibrosis

Year 2020, Volume: 6 Issue: 3, 333 - 339, 31.12.2020

Derya Yenibertiz , Berna Akıncı Özyürek , Mehmet Sinan Aydın Yurdanur Erdoğan

https://doi.org/10.19127/mbsjohs.818494

Cited By: 2

Abstract

Objective: Depression and anxiety are the comorbid diseases of Idiopathic Pulmonary Fibrosis (IPF) and these diseases are more frequently in patients with serious progressive types of IPF. The aim of this study was to use the Hospital Anxiety and Depression Scale (HADS) to evaluate the levels of depression and anxiety in IPF patients.
Methods: A total of 27 patients were included to the study. Demographic characteristics, pulmonary function tests, GAP indexes (gender, age, and physiology), 6-minute walk test (MWT) values were recorded from the patient files. To measure the levels of anxiety and depression in patients with IPF, the validated Turkish version of the HADS, including 14 questions, was used.
Results: Anxiety was determined in 33.3% of the patients and depression was detected in 37% of the patients. The patients’ avearage anxiety score was 5.5 and the mean depression score was 6.2. Desaturation in patients with anxiety was significantly higher (p<0.05) and was found to be higher in patients with depression (p<0.05). DLCO levels were detected to be lower in patients with depression (p <0.05).
Conclusion: The quality of life of patients diagnosed with IPF can be improved by psychiatric assessment and adequate supportive care, including antidepressant medication and psychological therapy.

Keywords

Anxiety, depression, Idiopathic Pulmonary Fibrosis

References

• Akhtar AA., Ali MA., Smith RP. Depression in patients with idiopathic pulmonary fibrosis. Chron Respir Dis. 2013 Aug;10(3):127-33. Atlantis E., Fahey P., Cochrane B., Smith S. Bidirectional associations between clinically relevant depression or anxiety and COPD: a systematic review and meta-analysis. Chest. 2013 Sep;144(3):766-77.
• Amin A., Zedan M., Halima K., Ismail A. Depression In Patients With Idiopathic Pulmonary Fibrosis. AAMJ. 2014 Oct; 12(4).
• Aydemir O., Guvenir T., Kuey L., Kultur S. Reliability and Validity of the Turkish version of Hospital Anxiety and Depression Scale. Turkish journal of psychiatry. 1997;8: 280-7.
• De Vries J., Kessels BL., Drent M. Quality of life of idiopathic pulmonary fibrosis patients. Eur Respir J 2001 May; 17(5): 954–61.
• Holland AE., Fiore JF., Bell EC., Goh N., Westall G., Symons K. et al. Dyspnoea and comorbidity contribute to anxiety and depression in interstitial lung disease. Respirology. 2014 Nov;19(8):1215-21.
• Lee YJ, Choi SM., Lee YJ., Cho YJ., Yoon HI., Lee JH. et al. Clinical impact of depression and anxiety in patients with idiopathic pulmonary fibrosis. PloS one, 2017 Sep 11; 12(9).
• Maurer, J., Rebbapragada V., Borson S, Goldstein R, Kunik ME, Yohannes AM. et al. Anxiety and depression in COPD: current understanding, unanswered questions, and research needs. Chest. 2008 Oct., 134(4), 43-56.
• Moussavi S., Chatterji S., Verdes E., Tandon A., Patel V., Ustun B. Depression, chronic diseases, and decrements in health: results from the World Health Surveys. Lancet. 2007 Sep 8;370(9590):851-8.
• Ng TP., Niti M., Tan WC., Cao Z., Ong KC., Eng P. Depressive symptoms and chronic obstructive pulmonary disease: effect on mortality, hospital readmission, symptom burden, functional status, and quality of life. Arch Intern Med. 2007 Jan 8;167(1):60-7.
• Pink K., Boylan J., Hope-Gill B. An Observational Study of Anxiety and Depression in Idiopathic Pulmonary Fibrosis. Advances in Research. 2014 Apr; 2(6): 320–31
• Raghu G., Remy-Jardin M., Myers JL., Richeldi L., Ryerson CJ., Lederer DJ. et al. American Thoracic Society, European Respiratory Society, Japanese Respiratory Society, and Latin American Thoracic Society. Diagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline. Am J Respir Crit Care Med. 2018 Sep 1;198(5):e44-e68.
• Ryerson CJ., Berkeley J., Carrieri-Kohlman VL., Pantilat SZ., Landefeld CS., Collard HR. Depression and functional status are strongly associated with dyspnea in interstitial lung disease. Chest. 2011 Mar;139(3):609-16.
• Ryerson CJ., Arean PA., Berkeley J., Carrieri-Kohlman VL., Pantilat SZ., Landefeld CS. Et al. Depression is a common and chronic comorbidity in patients with interstitial lung disease. Respirology. 2012 Apr;17(3):525-32.
• Schneider C., Jick SS., Bothner U., Meier CR. COPD and the risk of depression. Chest. 2010 Feb;137(2):341-7.
• Solano JP., Gomes B., Higginson IJ. A comparison of symptom prevalence in far advanced cancer, AIDS, heart disease, chronic obstructive pulmonary disease and renal disease. J Pain Symptom Manage. 2006 Jan;31(1):58-69.
• Willgoss TG., Yohannes AM. Anxiety disorders in patients with COPD: a systematic review. Respir Care.2013 May; 58: 858–66.
• Xu W., Collet JP., Shapiro S., Lin Y., Yang T., Platt RW. et al. Independent effect of depression and anxiety on chronic obstructive pulmonary disease exacerbations and hospitalizations. Am J Respir Crit Care Med. 2008 Nov 1;178(9):913-20. Yalnız E, Polat G, Demirci F, Deniz S, Karadeniz G, Aydınlı E. et al. Are idiopathic pulmonary fibrosis patients more anxious and depressive than patient's with other interstitial lung disease? Sarcoidosis Vasc Diffuse Lung Dis. 2019;36(4):294-301.
• Zheng D., Macera CA., Croft JB., Giles WH., Davis D., Scott WK. Major depression and all-cause mortality among white adults in the United States. Ann Epidemiol. 1997 Apr;7(3):213-8